Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination

This letter to the editor comments on a recently published article on seroconversion rates after COVID-19 vaccination.

Detalles Bibliográficos
Autores principales: Sriwijitalai, Won, Wiwanitkit, Viroj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632302/
https://www.ncbi.nlm.nih.gov/pubmed/36018054
http://dx.doi.org/10.1093/oncolo/oyac169
_version_ 1784824004837638144
author Sriwijitalai, Won
Wiwanitkit, Viroj
author_facet Sriwijitalai, Won
Wiwanitkit, Viroj
author_sort Sriwijitalai, Won
collection PubMed
description This letter to the editor comments on a recently published article on seroconversion rates after COVID-19 vaccination.
format Online
Article
Text
id pubmed-9632302
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-96323022022-11-04 Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination Sriwijitalai, Won Wiwanitkit, Viroj Oncologist Letter to the Editor This letter to the editor comments on a recently published article on seroconversion rates after COVID-19 vaccination. Oxford University Press 2022-08-26 /pmc/articles/PMC9632302/ /pubmed/36018054 http://dx.doi.org/10.1093/oncolo/oyac169 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Sriwijitalai, Won
Wiwanitkit, Viroj
Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
title Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
title_full Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
title_fullStr Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
title_full_unstemmed Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
title_short Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
title_sort therapy in patients with hematologic malignancies, seroconversion rates, and sars-cov-2 vaccination
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632302/
https://www.ncbi.nlm.nih.gov/pubmed/36018054
http://dx.doi.org/10.1093/oncolo/oyac169
work_keys_str_mv AT sriwijitalaiwon therapyinpatientswithhematologicmalignanciesseroconversionratesandsarscov2vaccination
AT wiwanitkitviroj therapyinpatientswithhematologicmalignanciesseroconversionratesandsarscov2vaccination

Ejemplares similares